# 2013 Research Annual Report

# **Psychiatry**



# **Division Details**

### **Division Data Summary**

RESEARCH AND TRAINING DETAILS	
Number of Faculty	21
Number of Joint Appointment Faculty	3
Number of Support Personnel	30
Direct Annual Grant Support	\$1,213,386
Direct Annual Industry Support	\$65,623
Peer Reviewed Publications	21
CLINICAL ACTIVITIES AND TRAINING	
Number of Clinical Staff	57
Number of Other Students	20
Inpatient Encounters	19,953
Outpatient Encounters	34.141

#### **Division Photo**



Row 1: T Shaeffer, S Sampang Row 2: J Bow den, B Keeshin, E Harris, C Engel Row 3: J Strawn, B Kurtz, A Cavalieri, M Sorter, C Erickson

# Significant Accomplishments

# Improving Our Understanding of Aggression in Children

Drew Barzman, MD, has created a unique database of more than 3,000 individuals to conduct studies of pediatric aggression. Recent studies have explored the relationship of fMRI and salivary biomarkers with aggressive behavior and are evaluating the utilization of such measures to assist in predicting aggressive acts.

# Fragile X Center Studies New Treatments

Craig Erickson, MD, established our Fragile X Research and Treatment Center in in 2012 and has started several translational research projects. Erickson is using a four-year, \$1 million grant from The John Merck Fund to conduct a double-blind, placebo-controlled study of acamprosate in youth with Fragile X. Our Center also has received three other industry contracts to study novel investigational drugs in youth and adults with Fragile X Syndrome.

The Fragile X Center also has started a translational treatment mouse research program under the direction of Tori Schaefer, PhD. She is using a grant from the FRAXA Research Foundation to study of a novel modulator of GABA neurotransmission in Fragile X knockout mice.

The Fragile X Center also has begun collaborating with the National Fragile X Foundation and the Centers for Disease Control an Prevention on a longitudinal behavior tracking study.

#### **Expanding the Continuum of Care**

In 2012, we opened a partial psychiatric hospitalization program at our new Green Township campus to help meet the growing need for pediatric and adolescent psychiatric care in our region.

The new program offers five to 10 days of intensive management provided by physicians, nurses, social workers, and psychologists, while allowing patients to continue residing at home. Frequent areas of treatment focus include depression, self-injury, school refusal, anxiety, and disruptive behavior.

Thanks to a generous donation from the Pichler family, our Green Township program brings our partial hospitalization capacity to about 4,000 patient days per year. Overall, increased utilization of advanced practice nurses, psychiatric social workers, and clinical counselors have increased our outpatient visits to more than 29,000 in the past fiscal year.

# Research Highlights

#### FRAGILE X RESEARCH AND TREATMENT CENTER

Dr. Craig Erickson established the Fragile X Research and Treatment Center within the Division of Child and Adolescent Psychiatry in 2012. The center has started several new translational treatment development research projects within the last year. In 2013 Dr. Erickson received a four year one million dollar grant from The John Merck Fund to conduct a double-blind, placebo-controlled study of acamprosate in youth with Fragile X. The Fragile X Center additionally received three industry contracts to study novel investigational drugs in youth and adults with Fragile X Syndrome. The Fragile X Center has also started a translational treatment development mouse research program under the direction of Tori Schaefer, PhD. Dr. Schaefer received a grant from the FRAXA Research Foundation to conduct a study of a novel modulator of GABA neurotransmission in Fragile X knockout mice. The Fragile X Center continues to collaborate worldwide with investigators in the development of new targeted treatments for the disorder. Finally, the Fragile X program began collaboration with the National Fragile X Foundation and the United States Centers for Disease Control (CDC) on a longitudinal behavior tracking study in the disorder.

# **Division Publications**

- 1. Amatya PL, Barzman DH. The Missing Link between Juvenile Delinquency and Pediatric Posttraumatic Stress Disorder: An Attachment Theory Lens. ISRN Pediatr. 2012; 2012:134541.
- 2. Barzman D, Mossman D, Sonnier L, Sorter M. Brief Rating of Aggression by Children and Adolescents (BRACHA): a reliability study. *J Am Acad Psychiatry Law.* 2012; 40:374-82.
- 3. Chang K, Delbello M, Chu WJ, Garrett A, Kelley R, Mills N, Howe M, Bryan H, Adler C, Eliassen J, Spielman D, Strakowski SM. **Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression**. *J Child Adolesc Psychopharmacol*. 2012; 22:261-8.
- 4. Delgado SV, Strawn JR. Termination of psychodynamic psychotherapy with adolescents: A review and contemporary perspective. *Bull Menninger Clin.* 2012; 76:21-52.
- 5. DK L, DK S, CA E, B R, CY H, B M. Autism as an early neurodevleopmental disorder: Evidence for an sAPPα-mediated anabolic pathway.. Frontiers in Cellular Neuroscience. 2013; 7:94.
- Grupp-Phelan J, Delgado SV. Management of the Suicidal Pediatric Patient: An Emergency Medicine Problem. Clinical Pediatric Emergency Medicine. 2013; 14:12-19.
- 7. Harris E, Jacobs-Jablow S. How to Help your Struggling Child: When to Consider Seeking Professional Mental Health Support. *Cincinnati Parent*. 2013; .

- 8. Heffner JL, DelBello MP, Fleck DE, Adler CM, Strakowski SM. **Unplanned pregnancies in adolescents** with bipolar disorder. *Am J Psychiatry*. 2012; 169:1319.
- Ho JG, Caldwell RL, McDougle CJ, Orsagh-Yentis DK, Erickson CA, Posey DJ, Stigler KA. The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2012; 22:277-83.
- 10. Korostenskaja M, Harris E, Giovanetti C, Horn P, Wang Y, Rose D, Fujiwara H, Xiang J. Magnetoencephalography reveals altered auditory information processing in youth with obsessive-compulsive disorder. *Psychiatry Res.* 2013; 212:132-40.
- 11. McNamara RK, Strawn JR. Role of Long-Chain Omega-3 Fatty Acids in Psychiatric Practice. *PharmaNutrition*. 2013; 1:41-49.
- 12. McNamara RK, Strawn JR, Chang KD, DelBello MP. Interventions for youth at high risk for bipolar disorder and schizophrenia. *Child Adolesc Psychiatr Clin N Am.* 2012; 21:739-51.
- 13. Pathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, Delbello MP. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2013; 74:e100-9.
- 14. Patino LR, Adler CM, Mills NP, Strakowski SM, Fleck DE, Welge JA, DelBello MP. Conflict monitoring and adaptation in individuals at familial risk for developing bipolar disorder. *Bipolar Disord*. 2013; 15:264-71.
- 15. Southammakosane C, Danielyan A, Welge JA, Blom TJ, Adler CM, Chang KD, Howe M, DelBello MP. Characteristics of the child behavior checklist in adolescents with depression associated with bipolar disorder. *J Affect Disord*. 2013; 145:405-8.
- 16. Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. *Psychopharmacology (Berl)*. 2012; 223:237-45.
- 17. Strawn JR, Bitter SM, Weber WA, Chu WJ, Whitsel RM, Adler C, Cerullo MA, Eliassen J, Strakowski SM, DelBello MP. Neurocircuitry of generalized anxiety disorder in adolescents: a pilot functional neuroimaging and functional connectivity study. *Depress Anxiety*. 2012; 29:939-47.
- 18. Strawn JR, Chu WJ, Whitsel RM, Weber WA, Norris MM, Adler CM, Eliassen JC, Phan KL, Strakowski SM, DelBello MP. A pilot study of anterior cingulate cortex neurochemistry in adolescents with generalized anxiety disorder. *Neuropsychobiology*. 2013; 67:224-9.
- 19. Strawn JR, Sakolsky DJ, Rynn MA. Psychopharmacologic treatment of children and adolescents with anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2012; 21:527-39.
- 20. Strawn JR, Saldana SN. Treatment with adjunctive N-acetylcysteine in an adolescent with selective serotonin reuptake inhibitor-resistant anxiety. *J Child Adolesc Psychopharmacol.* 2012; 22:472-3.
- 21. Welge JA, DelBello MP. Treatment of youth with bipolar disorder: long-term versus maintenance. *Bipolar Disord*. 2013; 15:150-2.

# Faculty, Staff, and Trainees

**Faculty Members** 

Michael Sorter, MD, Associate Professor Leadership Director, Division of Psychiatry

Drew Barzman, MD, Assistant Professor

Leadership Director of Child & Adolescent Forensic Psychiatry Service

Sandra Batsel-Thomas, MD, Assistant Professor

Cynthia Daugherty, MD, Assistant Professor

Sergio Delgado, MD, Associate Professor

**Leadership** Director of Outpatient Services

Carol Engel, MD, Assistant Professor

Leadership Residency Training Director, Triple Board Program

Craig Erickson, MD, Assistant Professor

Elana Harris, MD, Assistant Professor

Mark Johnson, MD, Assistant Professor

Brian Kurtz, MD, Assistant Professor

**Leadership** Director of Consultation Services

Mary Matias-Akhtar, MD, Assistant Professor

Daniel Nelson, MD, Associate Professor

Leadership Director of Inpatient Services

Hilton Rodriguez, MD, Assistant Professor

Suzanne Sampang, MD, Assistant Professor

Leadership Residency Training Director, Child & Adolescent Psychiatry

Raymond Troy, MD, Assistant Professor

Daniel Vogel, MD, Assistant Professor

Logan Wink, MD, Assistant Professor

Joint Appointment Faculty Members

Melissa DelBello, MD, Associate Professor (Psychiatry)

**Jeffrey Strawn, MD**, Assistant Professor (Psychiatry)

#### **Trainees**

Anthony Cavalieri, MD, PGY 6, Wayne Sate University School of Medicine, Detroit Michigan

Deborah Amann, MD, PGY 5, Wright State University, Dayton Ohio

Reyna Gilmore, MD, PGY 5, Howard University College of Medicine, Washington DC

Deana McReynolds, MD, PGY 4, Murray State University, Murray KY

John Vraciu, MD, PGY 4, Kent State University, Kent OH

Courtney Cinko, MD, PL 3, Rush Medical College, Chicago IL

Kelli Dominick, MD, PL 2, Boston University School of Medicine

Diana Frey, MD, PL 4, Mayo Medical School, Rochester MN

Delanie Janke, MD, PL 4, University of Texas Medical Branch, Galvetton TX

Paul Houser, MD, PL 3, St. Louis University School of Medicine, St. Louis MO

Mercedes Kwiatkowski, MD, PL 5, Georgetown University School of Medicine

Ernest Pedapati, MD, PL 4, University of Massachusetts Medical School, North Worcester MA

Lindsay Tobler, MD, PL 5, University of Missouri, Columbia MO

Sophianne Subbiah, MD, PL 1, University of Iowa School of Medicine, Iowa City, IA

Theresa Umhoefer, MD, PL 1, University of Wisconsin

Melissa Schuman-Wagner, MD, PL 1, Medical College of Wisconsin, Milwaukee, WI Elizabeth Wassenaar, MD, PL 5, Jefferson Medical College of Thomas Jefferson University, Philadelphia PA Yesie Yoon, MD, PL 2, Yonsei University

# **Division Collaboration**

# Neurology » David Franz and Tracy Glauser

Tuberous Sclerosis Clinic, Pharmacogenetics Seizure Therapy

#### Adolescent Medicine » Frank Biro and Laurie Mitan

Mental Health Treatment Clinic in Adolescent Medicine Center and Eating Disorders

#### DDBP » Patricia Manning, Rena Sorensen, and Michael Lind

Center for School Crisis and Bereavement, Kelly O'Leary Center/Autism Treatment, Comorbid Intellectual Disability and Mental Illness Services

#### Pediatric Primary Care » Mona Mansour

Mental Health Consultation

### Behavioral Medicine and Clinical Psychology » Lori Stark and Jeff Epstein

ADHD Consultations to Pediatricians, Outpatient Care, Inpatient Consultations

### Hematology/Oncology » John Perentesis

Specialized Consultation Service

# Pediatric Endocrinology » Larry Dolan and David Klein

Management of Atypical Antipsychotic/Metabolic Syndrome

#### **Human Genetics** » Howard Saal

Velocardio Facial Syndrome

#### Mayerson Center » Bob Shapiro

Trauma Treatment and Clinic

# Grants, Contracts, and Industry Agreements

Grant and Contract Awards Annual Direct

ERICKSON, C

#### Acamprosate in Fragile X Syndrome

The John Merck Fund

01/01/13-12/31/16 \$250,000

#### Acamprosate in Youth with Autism Spectrum Disorder

Autism Speaks Grant Administration

12/01/12-11/30/15 \$136,108

#### Extracellular Signal-Related Kinase Biomarker Development in Autism

Simons Foundation

09/01/12-08/31/14 \$101,486

#### D-Cycloserine for Enhancement of Social Skills Training in Pervasive Development

Department of Defense(Indiana University Health)

W81XWH-09-1-0091	08/01/12-02/14/14		\$158,330
Acomprosate in Youth with Autistic I	Disorder		
The American Academy of Child and A	Adolescent Disorder		
	7/16/2012-12/31/2012		\$14,060
KOWATCH, R			
Longitudinal Assessment of Manic S	ymptoms		
National Institutes of Health			
R01 MH 073816	07/01/10-02/28/15		\$473,402
SORTER, M			
Effective Trauma Detection and Trea	_		
Health Foundation of Greater Cincinnation	ati		
	04/01/13-03/31/14		\$45,000
WINK, K			
A Phase II Trial of Levodopa in Angel	man Syndrome		
Food and Drug Administration(Childre	en's Hospital Boston)		
R01 FD 003523	08/01/12-07/31/13		\$35,000
	Current Year Direct	\$1,213,386	
Industry Contracts			
DELGADO, S			
Pfizer, Inc			\$19,362
ERICKSON, C			
Roche Laboratories, Inc			\$28,998
Seaside Therapeutics, Inc			\$10,010
WINK, L			
SynapDx			\$7,253
	Cı	ırrent Year Direct Receipts	\$65,623
		Total	\$1,279,009